We report that oligonucleotides can be introduced into the mitochondria of living mammalian cells by annealing them to peptide nucleic acids coupled to mitochondrial targeting peptides. These complexes are imported into the mitochondrial matrix through the outer and inner membrane import channels of isolated mitochondria. They are also imported into the mitochondria of cultured cells, provided that the cytosolic uptake of the complexes is facilitated by using synthetic polycations or membrane permeabilizing toxins. Our method now promises to provide a viable strategy for the genetic modification of the mitochondria in cultured cells, animals and patients.
INTRODUCTION
No routinely successful method has been developed for introducing exogenous DNA into the mitochondria of living mammalian cells. To reach the mitochondrial matrix where the mitochondrial DNA (mtDNA) resides, the exogenous DNA must traverse three membranes: the plasma membrane, the mitochondrial outer membrane and the mitochondrial inner membrane.
DNA has been introduced into the mitochondria of plant cells and yeast by biolistic transformation (1) , though this procedure has not been productive for mammalian cells. DNA has been introduced into isolated mammalian mitochondria by electroporation (2) , but there are no reports of repopulation of mammalian cells with electroporated mitochondria. Mitochondria isolated from somatic cells have been microinjected into cultured cells or oocytes (3) , but this method uses naturally occurring mitochondrial genotypes and microinjection is impractical for the genetic manipulation of large numbers of cultured cells or for mitochondrial gene therapy in animal or human tissues.
DNA has also been introduced into isolated mitochondria by covalent-linkage of either oligonucleotides (4) or double stranded DNA (5) to N-terminal mitochondrial protein targeting peptides. Such conjugates are imported into the mitochondria via the "transport through the outer membrane" (TOM) and "transport through the inner membrane" (TIM) multi-protein import channel complexes (6) . When fluorescently labeled short oligonucleotides, covalently linked to a mitochondrial targeting peptide, were introduced into cultured fibroblasts using liposomes, the fluorescence became associated with mitochondria-like structures. However, the matrix localization of the oligonucleotides was not established (7) .
As an alternative to DNA, peptide nucleic acids (PNAs) (8) have been tried. PNAs use a peptide bond backbone instead of the sugar phosphate backbone of DNA or RNA to connect nucleic acid bases. PNAs have been conjugated to N-terminal mitochondrial targeting peptides and these are imported into the mitochondria. However, PNAs cannot be incorporated into the mtDNA and could not be shown to affect gene expression in cells (9) .
While apparently biologically inactive in themselves, PNAs have a very high affinity for base pairing with homologous oligonucleotides. This is because the peptide backbone eliminates the inter-strand repulsion that destabilizes double stranded nucleic acids (10) . Moreover, PNAs are very stable in biological systems (11, 12) .
We now report combining these various strategies into a successful method for introducing oligonucleotides into the mitochondria of living cells. An N-terminal mitochondrial targeting peptide is covalently coupled to a PNA encoding a portion of the sequence to be introduced into the mitochondrion. This targeting peptide-PNA conjugate is then annealed to an oligonucleotide with the desired sequence and the complex transferred into the cytosol using either polycations or transient membrane channels. This procedure efficiently delivered labeled oligonucleotides into the mitochondrial matrix, both in vitro and in vivo.
RESULTS

Preparation of PNA-Peptide/Oligonucleotide (PPO)-Complexes
When PNA-peptide conjugates (Table 1) were annealed to a 100-fold molar excess of fluorescein (FAM), digoxigenin (DIG) or gold-labeled oligonucleotide (Table 1) , more than 90% of PNA-Peptide conjugates were recovered as PNA-peptide/oligonucleotide (PPO) complexes (Fig. 1A) . Formation of PPO-complexes could be confirmed by separation of reaction products in TBE-Urea or TG-SDS-polyacrylamide gel systems. However, due to the different physical and chemical properties of different labels on the oligonucleotides and the chimeric nature of PNA-peptides, no single gel system proved to be optimal for all of the chimeric constructs and complexes. Therefore, products were purified by HPLC (Fig. 1B and C) and recovered in HBS or PBS for application to mitochondria or cells.
Import of PPO-Complexes into Isolated
Mitochondria PPO-complexes bearing DIG-labeled oligonucleotides were selectively taken up by isolated mouse liver mitochondria, and detected using anti-DIG antibodies. For PPO-complexes encompassing a yeast COX IV pre-peptide conjugated to a PNA (Y-conjugate), labeled oligonucleotides were detected primarily in the inner membrane and in the matrix (Fig. 2 ) of mitochondria. Similar results were obtained for PPO-complexes using a mouse thiolase pre-peptide PNA-conjugate (M-conjugate).
The requirement for a normal N-terminal targeting peptide (Y-or M-conjugate) for import of the PPO-complexes through the TOM-TIM channels and into the matrix was confirmed by replacing the normal targeting peptide with a randomized (scrambled) amino acid sequence (SCR-conjugate). The SCR-conjugate/PPO-complex gave only a weak interaction with the outer mitochondria membrane and no oligonucleotides were detected in the inner membrane or matrix fractions (Fig. 2) . Free oligonucleotides did not associate with the mitochondrial membranes at all.
The uptake of the PPO-complexes was about 50 fold higher with mitochondria energized by ATP then with ATP-depleted mitochondria (Fig. 2) , and the uptake was five times more rapid for the Y-conjugate/PPO-complexes than for the M-conjugate/PPO-complexes, as quantified by direct comparison of in vitro import into the mitochondrial matrix. Thus, the PPO-complexes are taken up by the mitochondria via targeting sequence-specific active transport.
Uptake of Y-Conjugate/PPO-Complexes into Mouse
Muscle Myoblast Cells PPO-complexes were next used to treat cultured mouse C2C12 myoblasts. The mitochondrial uptake of the Y- conjugate/PPO-complexes was compared with control SCR-conjugate/PPO-complexes. To facilitate introduction of the PPO-complexes into the cell cytoplasm, four different protocols were tried: direct exposure, encapsulation in liposomes, aggregation with polycations, or diffusion through transient plasma membrane pores generated by Streptolysin-O (SL-O). To monitor the oligonucleotide fate, the 5Ј ends were labeled with either fluorescein (FAM) or colloidal gold.
Passive Uptake of Mitochondrial-Targeted PPO-Complexes
Initially, 1 M PPO-complexes containing 1 M of FAMlabeled oligonucleotide (13) were apply directly to the myoblasts. At 30 min after exposure, myoblasts exposed to either PPO-complexes or free oligonucleotides showed intense, uniform, intracellular cytosolic fluorescence. By 1 hour after exposure the PPO-complex-associated oligonucleotide fluorescence was concentrated around the mitochondria with low cytoplasmic background (comparable to Fig. 3D ), while free oligonucleotide fluorescence was faint and dispersed throughout the cytoplasm.
High magnification fluorescent microscopy (up to 1250x) did not reveal any indication for staining of organelles other than the mitochondria in the focal plane used, when comparing the fluorescence patterns generated by the PPO-complexes and Mitotracker. Hence, cells are capable of taking up naked PPO-complexes and transporting them to the mitochondria.
To analyze the efficacy of introducing the PPO-complexes through the plasma membrane by liposomes, polycations, or SL-O pores; we reduced the PPO-complex concentration and thus the labeled oligonucleotide to 10 nM. This eliminated the background associated with the passive uptake of PPO-complexes observed at 1 M.
Lipotransfection
Liposomes (14) proved unsuitable for introduction of the PPO-complexes into the myoblast cytoplasm. After liposome-facilitated transformation, the fluorescence of liposome-encapsulated PPO-complexes with targeting peptides, either Y-conjugate or SCR-conjugate, remained associated with the outside of the cell (Fig. 3C ). This suggests that the hydrophobic targeting peptides became dissolved in the lipid bi-layer of the liposome and the plasma membrane rendering them inaccessible to the mitochondria. Indeed, cytosolic fluorescence was higher with liposome encapsulated oligonucleotides alone (Fig.  4A) or PPO-complexes lacking a targeting peptide (data not shown).
PEI-PPO-Complex Aggregate Transformation
The cytosolic delivery of PPO-complexes using branched chain polyethylenimine (PEI) was more successful. PEIs aggregate DNA, protecting it from endocytosis and endosomal degradation (15, 16) .
The optimal PEI molecular weight for PPO-complex delivery was 25 kDa and the optimal DNA to PEI ratio (N/P ratio) was 10/1. This created aggregates of 150 -300 nm with the maximum DNA fluorescence.
Exposure of myoblasts to PEI-PPO-complex aggregates containing 10 nM of oligonucleotides resulted in the efficient uptake of PEI-PPO complex aggregates into the cytosol. Initially the PPO-complexes were distributed peri-nuclearly and co-localizing with the lysosome-specific dye Lysotracker™ (Fig. 3C) . Subsequently, the oligonucleotide fluorescence became localized in bead-like structures of reduced size, creating a pattern in which some fluorescence remained co-localized with Lysotracker™, but most of the fluorescence co-localized with Mitotracker (Fig. 3A) and similar to Fig. 3D . Thus, Yconjugate/PPO-complexes were transferred from the lysosomal PEI-PPO-complex aggregates to the mitochondria.
The intensity of the mitochondrial oligonucleotide fluorescence was directly related to the proximity to the PEI-PPO-complex aggregates to the mitochondria. Mitochondria near the PEI-PPO-complex aggregates rapidly developed high-level fluorescence. The fluorescence then diffused along the mitochondria creating a fluorescent mitochondrial network, which was maintained for extended periods of time (Fig. 4B) .
While mitochondrial uptake was intense with the Yconjugate, it was absent with either the SCR-conjugate (Fig. 3A, SCR) or with PNAs lacking a targeting peptide (Fig. 3A {-pept} and Fig. 3B ), indicating that the targeting peptide sequence was essential for mitochondrial uptake. Surprisingly, the SCR-conjugate/PPO-complex resulted in intense nuclear fluorescence (Fig. 3A, {SCR}) .
It is unlikely that the Y-conjugate/PPO-complexes were simply stuck in the mitochondrial import channels, since the transfected cells did not show increased rates of cell death or in apoptotic changes in mitochondrial morphology such as fragmentation or "curling" of the mitochondrial network. Furthermore, the mitochondrial fluorescence diffused away from the PEI-PPO-complex aggregates along the mitochondrial network as if moving through an aqueous phase. Hence, it is most likely that the labeled oligonucleotides became localized in the mitochondrial matrix.
Streptolysin-O (SL-O) Permeabilization
PPO-complexes were also delivered to the cytosol using an optimized concentration of the bacterial toxin SL-O, which generates transient plasma membrane pores of up to 30 nm (17, 18) (Fig.4a) . Within 30 min after SL-O and Y-conjugate/PPO-complex treatment of the myoblasts, oligonucleotide fluorescence co-localized with Mitotracker (Fig. 3D) and was uniformly distributed throughout the mitochondria. While the oligonucleotide fluorescence per mitochondrial unit was lower with SL-O than for mitochondrial adjacent to PEI aggregates, a much larger proportion of the mitochondrial network became ARTICLE doi:10.1016/S1525-0016(03)00037-6 fluorescent with SL-O. Therefore, the overall mitochondrial uptake of the Y-conjugate/PPO-complex per cell was higher using SL-O than PEI (Fig. 4B) .
Following introduction by SL-O, the Y-conjugate/PPOcomplexes gave intense mitochondrial fluorescence, while SCR-conjugate/PPO-complexes gave only nuclear fluorescence (similar to Fig. 3A) . Following SL-O-stimulated Y-conjugate/PPO-complex exposure, the mitochondrial fluorescence slowly declined, suggesting that the labeled oligonucleotides in transformed mitochondria were degraded by proteolytic or nucleolytic processes in the mitochondrial matrix (Fig. 4B) . This contrasts to the stability of the PEI-PPO-complex aggregate mitochondrial fluorescence (Fig. 4B) . Perhaps the stability of the mitochondrial fluorescence associated with the PEI-PPO-complex aggregates results from the continuous release of the Y-conjugate bound oligonucleotide into the cytosol, which replenishes the degraded mitochondrial oligonucleotides.
Electron Microscopy
The deposition of the oligonucleotides from the Y-conjugate/PPO-complexes into the mitochondrial matrix of the myoblasts was confirmed using Undecagold™-labeled oligonucleotides. At 30 minutes after exposure to PEI-PPOcomplex aggregates, gold particles were observed by electron microscopy in cytoplasmic aggregates, presumably endolysosomes, as well as in association with the mitochondria (Fig. 5B) . Within 4 hours of exposure, single Undecagold™ particles were observed in the mitochondrial matrix ( Fig. 5A and C) . Undecagold™-labeled oligonucleotides annealed to the SCR-conjugate or to PNAs without a targeting peptide were not detected either inside or near the mitochondria. While the efficiency of mitochondrial import of Undecagold™-labeled oligonucleotides is generally reduced (19) , this result confirms that the Undecagold™-labeled oligonucleotides are transported into the mitochondrial matrix where they could then interact with the mtDNA.
DISCUSSION
Many attempts have been made to develop a reliable method for delivering DNA to the mitochondrial matrix from outside a mammalian cell, but to no avail. Now, however, we report the successful import of labeled DNA oligonucleotides into the mitochondrial matrix using PNAs conjugated to mitochondrial targeting peptides as vehicles for the transport of annealed oligonucleotides through the TOM-TIM protein import apparatus.
Proof that we have succeeded in introducing native DNA oligonucleotides into the mitochondrial matrix of living cells comes from several interrelated observations. First, we showed that isolated mitochondria could take up Y-conjugate/PPO-complexes into the mitochondrial inner membrane and matrix. Second, we demonstrated that uptake of the PPO-complexes required energized mitochondria and a legitimate mitochondrial targeting peptide. Third, we showed that Y-conjugate/PPO-complexes within myoblasts were localized in structures that had the morphology of mitochondria and co-localized with Mitotracker. Fourth, we demonstrated that Y-conjugate/PPOcomplexes containing gold-labeled oligonucleotides were localized within the mitochondrial matrix as revealed by electron microscopy. Finally, we showed that the mitochondrial uptake within cells did not occur unless we used a functional mitochondrial targeting peptide.
Having developed an effective system for introducing oligonucleotides through the mitochondrial membranes and into the matrix, we increased the efficiency of mitochondrial transformation by using PEI aggregates or SL-O channels to enhance cellular uptake of the PPO-complexes. SL-O uptake gave the highest overall mitochondrial fluorescence, but then slowly faded. PEI aggregates gave intense regional mitochondrial fluorescence, and the While considerable effort has been invested in optimizing our procedures, additional improvements may still be possible in the PPO-complex construction. Alternatives to the yeast COX IV mitochondrial targeting peptide may be more efficacious in mediating PNA/oligonucleotide uptake into the mitochondria (20) or may allow import of longer oligonucleotides. Modifications of the length and sequence of the PNA and the annealed oligonucleotide may enhance biological activity. The reason for the decline of the mitochondrial oligonucleotide fluorescence in the mitochondrial matrix needs to be determined and inhibited.
Still, having succeeded in introducing oligonucleotides into the mitochondria, we can now attempt to genetically modify the mtDNA. For example, an oligonucleotide could be introduced into the mitochondrial matrix that contains the base change in the 16S rRNA gene conferring resistance to the mitoribosome inhibitor chloramphenicol (CAP) (21) . If this oligonucleotide can act as a primer for mtDNA synthesis, it could generate a mtDNA harboring the CAP resistant mtDNA mutation.
Thus, our approach now has the potential of introducing a wide variety of mtDNA mutations into mammalian cell and animal tissue mtDNAs. This should permit generation of specific models for mtDNA disease, and raises the possibility of correcting pathogenic mtDNA mutations in cells or animals (22) .
MATERIALS AND METHODS
PNA-peptide conjugates. The PNA-targeting peptide conjugates were synthesized by Research Genetics (Huntsville, Alabama), using PNA-monomers, activator, and resins from Perseptive Biosystems (Framingham, Maryland). PNAs were synthesized using solid phase chemistry (23), ending in two "Ado"-linker molecules (8-amino-3, 6-dioxa-octanoic acid). The mitochondrial targeting peptides were then extended from these spacers by solid-phase Fmoc protein chemistry (24) . Conjugates (Table 1) were purified by RP-HPLC (25) and analyzed by MALDI-TOF MS (26) . M-conjugate. The "mouse," mitochondrial thiolase gene, 17 amino-acid pre-sequence (27) 
SCR-conjugate.
A "scrambled" peptide sequence of the same length as the M-chimera peptide was coupled to a PNA complementary to the mouse mtDNA nps 15986 -15998.
W/o-conjugate. A PNA molecule "without" pre-peptide was synthesized with 13 bases PNA complementary to nps 3871-3883 of pPCR 2.1.
To identify the conjugates in gel systems, the peptide part was labeled with the fluorescent probe FQ (3-(2-furoyl) quinoline-2-carboxaldehyde) (Atto-Tag™, Molecular Probes; Eugene, Oregon). Reaction products were purified by HPLC (see "Synthesis and Purification of Constructs"). 
